Characteristics of Taiwanese patients of PNH in the international PNH registry

Wen-Chien Chou¹, Wei-Han Huang², Ming-Chung Wang³, Chao-Sung Chang⁴, Shih-Peng Yeh⁵, Tzeon-Jye Chioʊ⁶, Yeu-Chin Chen⁷, Tseng-Hsi Lin⁸, Ming-Ching Shen⁹* and on behalf of the Taiwan PNH study group

From The 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis
Taipei, Taiwan. 6-9 October 2016

Abstract

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and acquired hematopoietic stem cell disease, with florid clinical presentations. Although this disease has been characterized in the western countries, its clinical and laboratory features in Taiwan have not yet been reported.

Results: As a part of an international prospective, non-interventional, observational registration trial of PNH, we have analyzed 63 patients recruited between 2009 and 2015 in Taiwan, with comparison to the 3857 patients in the rest of the world (ROW). The median age of diagnosis of our patients is 46 (range 9–84), without sex preponderance. While most of the clinical and laboratory presentations of our patients are similar to the ROW, ours have higher lactate dehydrogenase levels, lower hemoglobin, and higher frequencies of symptoms including shortness of breath and erectile dysfunction at the time of diagnosis. The incidence of thromboembolism was not statistically different between ours and the ROW (6.7 % vs 13.5 %, \( P = 0.178 \)). The patients in Taiwan were treated more frequently with corticosteroid (53.2 % vs 32 %, \( P < 0.001 \)), but less frequently with cyclosporine/anti-thymocyte globulin and heparin/warfarin, both \( P < 0.001 \).

Conclusions: This is the first systematic review on the Taiwanese PNH patients. Our analysis would provide key information about our PNH patients and would help understanding the basic characteristics of this rare disease in Taiwan.

Trial registration: This trial has been registered to ClinicalTrials.gov NCT01374360.

Keywords: Paroxysmal nocturnal hemoglobinuria, Taiwan

Abbreviations: CRF, Case report form; PNH, Paroxysmal nocturnal hemoglobinuria; ROW, Rest of the world; TE, Thromboembolism

Background

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired chronic disease characterized by complement-mediated hemolysis. PNH patients may suffer from life threatening complications such as thromboembolism (TE), pulmonary hypertension and impaired renal function; according to a western study, up to 35 % of PNH patients die within 5 years of diagnosis [1]. However, the clinical features of PNH patients in Taiwan have not yet been characterized. The International PNH Registry is a worldwide, observational, non-interventional study collecting safety and efficacy of eculizumab, as well as other clinical data from PNH patients, irrespective of treatment. This registry aims to enhance the understanding of the natural history of this rare disease, hoping to improve the diagnosis and optimize patient management and outcomes.

The natural history of PNH has been investigated via some analyses with different population sizes [1–5]. Schrezenmeier et al. reported the characteristics of 1610 patients in a global registry [6]. It is the first time now that we look at the baseline characteristics of this disease in Taiwanese PNH patients in this global PNH registry.
The data include demographics, clinical characteristics as well as concomitant medications. We describe the similarities and differences between Taiwanese PNH population and the rest of the world (ROW).

Methods

Patient population

The international PNH registry is a prospective, non-interventional, observational study. The Registry collects information from patients monitored in current medical practice irrespective of past, present, or future treatment policies. The registry was approved by the institutional review boards (or equivalent) of participating centers, and all patients provided written informed consent prior to inclusion. The registry is sponsored by Alexion Pharmaceuticals, Inc., and is overseen by an independent executive committee of international PNH experts.

Patients of any age with a clinical diagnosis of PNH confirmed by Ham test or Sucrose-Lysis test in the pre-flow cytometry era and/or detectable PNH clone of 0.1 % or confirmed by Ham test or Sucrose-Lysis test in the pre-flow cytometry era and/or detectable PNH clone of 0.1 % or more were eligible for this registry in Taiwan. A total of 63 PNH patients were enrolled in 11 institutes in Taiwan from 2009 to 2015.

Data collection

Data is collected via the case report form (CRF). Data captured in the registry include patients’ demographics, medical history, comorbidities, disease characteristics, symptoms, transfusion requirements, thrombotic events, and treatments. The lab data captured include lactate dehydrogenase (LDH) levels, hemoglobin levels, PNH clone sizes, renal function, and others. PNH-related symptoms, including abdominal pain, dyspnea, short of breath, erectile dysfunction, fatigue and hemoglobinuria were collected via history taking by the physicians.

Baseline is defined as the start date of eculizumab for treated patients or registry enrollment date for other patients. Analyses are performed with available data for each parameter. The number of patients contributing data for each assessment might not be consistent. For parameters that are collected only after enrollment, the available population will reflect the patients who started treatment after enrollment. Continuous variables were described using standard summary statistics; categorical variables were described using frequencies and percentages. \( P < 0.05 \) was considered statistically significant.

Results

Patients’ demographics and clinical characteristics

As of 2 Dec 2015, 63 patients from 11 centers in Taiwan were enrolled in the international PNH registry. 100 % of patients were from Asia. Patients’ demographics and clinical characteristics of the 63 enrolled patients are provided in Table 1.

The median patient age at enrollment was 46 years (rang 9–84 years), and 49.2 % of patients were female. Median disease duration from disease onset was 4.5 years (range from 0.1 to 34.8 years).

Similar to the ROW, most of the PNH patients in Taiwan have PNH clone size more than 50 % (63.6 %), whereas more than % of the PNH patients have clone size smaller than 10 % (27.3 % in Taiwan). The median LDH level at enrollment was 4.9 fold of the upper limit normal (ULN), higher than the ROW (\( P = 0.005 \)). 80 % of the patients had LDH higher than 1.5 fold of ULN in Taiwan, whereas in the ROW around 58.6 % of the patients reached 1.5 fold of ULN (\( p = 0.039 \)). Hemoglobin levels in Taiwan PNH patients were also significantly lower than the ROW (80 g/L vs. 99.0 g/L, \( p < 0.001 \)). Other parameters such as platelets \( 112 \times 10^9/L \), serum creatinine 66.3 umol/L, proteinuria (12.5 % trace, 37.5 % 1+ to 4+, in 36 patients) and eGFR 95.8 mL/min were not significantly different compared to the ROW.

6.7 % (4 out of 60) of the patients in Taiwan had a history of thrombotic events (TE), compared to 13.5 % in the ROW (\( p = 0.178 \)). 12.1 % (7 out of 58) had a history of impaired renal function in Taiwan, similar to 12.6 % observed in the ROW. Symptoms such as shortness of breath (59.3 %), erectile dysfunction (60.7 %) and hemoglobinuria (68.5 %) in Taiwan were more common than the ROW (41.9 %, 23.0 %, and 45.7 % respectively). The symptoms such as fatigue (81.5 %), abdominal pain (31.5 %), and dysphagia (13.0 %) were not different compared to ROW.

Concomitant medication

Although the hemoglobin levels were lower in Taiwan than the ROW, the history of RBC transfusion in Taiwan PNH patients was 67.8 %, comparable to the ROW (67.8 % vs 57.0 %, \( p = 0.274 \)). The corticosteroid use in Taiwan was significantly more frequent than the ROW (53.2 % vs. 32 %, \( p < 0.001 \)); whereas heparin/warfarin and cyclosporine/ATG use in Taiwan was much lower than the ROW, 3.3 % vs. 19.5 %, 12.9 % vs. 34.2 % respectively (\( p < 0.001 \)) (Table 2).

Discussion

This is the first time to have a systematic review on the Taiwanese PNH patients. This analysis provides key information of our PNH patients and would definitely help understanding the basic characteristics of this rare disease in Taiwan.

Our analysis of these 63 Taiwan PNH patients in the international PNH registry demonstrates the median LDH level at enrollment was 4.9 fold of the ULN, higher than the ROW 2.0 fold. Lee et al. reported in the similar registry data of 301 Korean PNH patients whose LDH levels were 4.1 fold of the ULN, similar to our finding [5].
In our cohort, the hemoglobin level is 80 g/L, significantly lower than 99 g/L of the ROW. In a large study by Nishimura et al., the 209 Japanese PNH patients also had lower hemoglobin concentration (82 g/L) compared to the Duke patients (97 g/L) [7]. Whether these differences in hemoglobin levels reflect the basic difference between the eastern and western populations needs further investigation in a larger cohort.

In our analysis, some initial symptoms were quite different between ours and the ROW patients. Significantly more PNH patients in Taiwan had classical symptoms of PNH, such as short of breath, hemoglobinuria, erectile dysfunction, while PNH patients in the ROW had higher incidence of thrombosis. The reasons for this discrepancy await for further confirmation in a larger cohort, however the short of breath, hemoglobinuria, and erectile dysfunction could

Table 1 Patients’ demographics and clinical characteristics at enrollment into the International PNH Registry, Taiwan versus the rest of the world (ROW)

| Parameter                                | Taiwan Patients (n = 63) | ROW (n = 3857) | p-value |
|------------------------------------------|--------------------------|----------------|---------|
| Age, years, median (range)               | 46.0 (9, 84)             | 43.0 (0, 104)  | 0.331   |
| Females, n (%)                           | 31 (49.2)                | 2072 (53.7)    | 0.525   |
| Age at disease start, years, median (range) | 37.5 (8, 84) (n = 62)   | 34.0 (0, 90) (n = 3773) | 0.483 |
| Disease duration, years, median (range)  | 4.5 (0.1, 34.8) (n = 62) | 3.0 (0.0, 100.4) (n = 3773) | 0.890 |
| GPI-Deficient Granulocytes, n (%)        | (n = 11)                 | (n = 1619)     | 0.980   |
| < 10 %                                   | 3 (27.3)                 | 482 (29.8)     |         |
| >=10 % to < 50 %                        | 1 (9.1)                  | 317 (19.6)     |         |
| >= 50 %                                  | 7 (63.6)                 | 820 (50.6)     |         |
| LDH Ratio (xULN), median (Q1, Q3)        | 4.9 (1.9, 9.1) (n = 25)  | 2.0 (1.0, 5.2) (n = 2398) | 0.005*
| > 1.5, n (%)                             | 20 (80.0)                | 1406 (58.6)    |         |
| Hemoglobin (g/L), median (Q1, Q3)        | 80.0 (68.0, 105.0) (n = 51) | 99.0 (84.0, 118.0) (n = 2996) | <0.001*
| Platelets (x10^9/L), median (Q1, Q3)     | 112.0 (51.0, 186.0) (n = 51) | 114.0 (51.0, 176.0) (n = 2990) | 0.680
| Serum Creatinine (umol/L), median (Q1, Q3) | 66.3 (53.0, 97.2) (n = 36) | 73.0 (61.9, 91.0) (n = 2746) | 0.36
| Proteinuria, n (%)                       |                          |                | 0.056   |
| Trace                                    | 2 (12.5)                 | 93 (10.0)      |         |
| 1+ to 4+                                 | 6 (37.5)                 | 158 (16.9)     |         |
| eGFR (mL/min), median (Q1, Q3)           | 95.8 (70.1, 116.5) (n = 36) | 95.6 (73.9, 114.1) (n = 2638) | 0.994
| < 30, n (%)                              | 3 (8.3)                  | 62 (2.4)       | 0.143   |
| 30–< 60                                  | 3 (8.3)                  | 329 (12.5)     |         |
| 60– < 90                                 | 8 (22.2)                 | 726 (27.5)     |         |
| > = 90                                   | 22 (61.1)                | 1521 (57.7)    |         |
| Neutrophils (x 10^9/L), median (Q1, Q3)  | 2.0 (1.0, 2.9) (n = 27)  | 1.9 (1.1, 2.9) (n = 2674) | 0.696
| History of Abdominal Pain, n (%)         | 17 (31.5)                | 943 (33.5)     | 0.884   |
| History of Dysphagia, n (%)              | 7 (13.0)                 | 434 (15.4)     | 0.848   |
| History of Shortness of Breath, n (%)    | 32 (59.3)                | 1180 (41.9)    | 0.012*  |
| History of Erectile Dysfunction, n (%)   | 17 (60.7)                | 271 (23.0)     | <0.001* |
| History of Fatigue, n (%)                | 44 (81.5)                | 2214 (78.5)    | 0.738   |
| History of Hemoglobinuria, n (%)         | 37 (68.5)                | 1288 (45.7)    | 0.001*  |
| History of Bone Marrow Disorder, n (%)   | 36 (58.1)                | 2265 (60.2)    | 0.794   |
| History of TE, n (%)                     | 4 (6.7)                  | 502 (13.5)     | 0.178   |
| History of any RBC Transfusion, n (%)    | 40 (67.8)                | 1816 (57.0)    | 0.274   |
| History of Impaired Renal Function, n (%)| 7 (12.1)                 | 456 (12.6)     | >0.999  |
| History of Pulmonary Hypertension, n (%) | 0 (0.0)                  | 68 (1.9)       | 0.627   |
| Ever Treated with Eculizumab, n (%)      | 25 (39.7)                | 1666 (43.2)    | 0.610   |

*p <0.05
possibly be directly correlated with lower hemoglobin and higher LDH levels in Taiwan.

In a recent study, Lee et al. reported the incidence of thrombosis in the Korean National PNH Registry and demonstrated an incidence of thrombosis of 17.9% [5]. A retrospective French study of 460 PNH patients also demonstrated 10-year cumulative incidence of 31% [2]. Our investigation showed a much lower incidence of thrombosis than the previous studies. Recently it has been reported that the incidence of thrombosis in PNH is likely to be underestimated as a result of subclinical pulmonary embolism or myocardial ischemia observed in 6 of 10 patients in one study [8] and evidence of subclinical myocardial damage in 2 of 10 patients in another study [9]. The lower incidence of thrombosis in Taiwan PNH group is consistent with the previous observations. In addition, the lower heparin/warfarin use may reflect less TE observed in Taiwan PNH patients.

The corticosteroid is widely used in Taiwan PNH patients compared to the patients in the ROW (53.2% vs 32%, *P*-value < 0.001). Corticosteroid as a treatment option for both chronic hemolysis and acute hemolytic exacerbations in PNH, is a subject of debate [10–12]. The main value of corticosteroid may be in attenuating acute hemolytic exacerbations. The value of steroid in treating chronic hemolysis is limited by toxicity. Brief pulses of prednisone may reduce the severity and duration of the crisis while avoiding the untoward consequences associated with long term use. However, in the recent study, Jang et al. showed the corticosteroid was the most frequently used medication in their patients (77%) but there was no difference in mortality between the 104 patients who received corticosteroids for >5.4 years (13%) and the 197 patients who received corticosteroid for < 5.4 years or had not received corticosteroid at all (15%; *P* = 0.520) [13]. We should be very cautious about the use of corticosteroid in PNH patients due to the lack of definitive efficacy and the side effects.

### Conclusions

In summary, this is the first systematic review for Taiwan PNH patients. We will need more patients and longer follow-up for better understanding about the characteristics and long-term outcome of PNH patients in Taiwan.

### Acknowledgements

We thank all the following co-investigators: Hwei-Fang Tien, Jih-Luh Tang, Ming Yao, Shiang-Hsiang, Bor-Sheng Ko, Shuo-Chun Hsu, Hsin-An Hou, and Yung-Li Yang (all from the National Taiwan University Hospital); Liang-Tsai Hsiao, Jyh-Pyng Gau, Chun-Yu Liu, Chia-Jen Liu, Yuan-Bin Yu, and Jeong-Shi Lin (all from Taipei Veterans General Hospital); Ching-Liang Ho, Ming-Shen Dai, Ping-Ying Chang, Tzu-Chuan Huang, Jia-Hong Chen, and Yi-Ying Wu (all from the Tri-Service General Hospital); Li-Yuan Bai and Chin-Chan Lin (both from China Medical University Hospital); Cheng-Shyong Chang, Chuan-Cheng Wang, Chih-Yuan Chung, Hsuan-Yu Lin, Kuan-Ming Lai, Jen-Tsun Lin, and Ching-Yeh Lin (all from Changhua Christian Hospital); Sung-Nan Pei, Ming-Chun Ma, and Chun-Kai Liao (all from Kaohsiung Chang Gung Memorial Hospital); Ta-Chih Liu, Hua-Hua Hsiao, Yi-Chang Liu, Jui-Feng Hsu, Shih-Feng Cho, Cheng-Han Wu, and Yu-Fen Tsai (all from Kaohsiung Medical University Hospital); Ming-Sun Yu, Shi-Yer Lin, Yu-Hsiang Chang, and Ying-Chung Hong (all from Kaohsiung Veterans General Hospital); Yi-Feng Wu and Tso-Fu Wang (both from Hualien Tzu Chi Hospital); Yu-Chun Sun, Jo-Lin Lo, Pang-Yu Lai, Yeh Tang, and Sheng-Yen Hsiao (all from Kaohsiung E-Da Hospital). We also thank all the study coordinators and research assistants for their help.

### Declaration

Publication fees for this article have been funded by APSTH 2016. This article has been published as part of Thrombosis Journal Volume 14 Supplement 1, 2016. The full contents of the supplement are available at https://thrombosisjournal.biomedcentral.com/articles/supplements/volume-14-supplement-1.

### Availability of data and material

The data and material are available through the agreement of the global registration trial team.

### Authors’ contributions

W-CC wrote the manuscript; M-CSH coordinated and oversaw the study; W-HH, M-CW, C-SC, S-PY, T-JC, Y-CC, T-HL contributed important materials and suggestions. All authors read and approved the final manuscript.

### Competing interests

The authors declare that they have no competing interests.

### Consent for publication

We consent for publication; no document is needed.

### Ethics approval and consent to participate

The registry was approved by the institutional review boards (or equivalent) of participating centers, and all patients provided written informed consent prior to inclusion. This trial has been registered to ClinicalTrials.gov NCT01374360.

### Author details

1. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Hualien, Taiwan. 3. Division of Hematology and Oncology Department of Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 4. Department of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 5. Department of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan. 6. Department of Medicine and Division of Transfusion Medicine Taipei Veterans General Hospital, Taipei, Taiwan. 7. Department of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan.

### Published: 4 October 2016
References

1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.

2. de Latour RP, Mary JY, Salanoubat C, Temiou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–106.

3. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126:133–8.

4. Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol. 2011;87:37–45.

5. Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97:749–57.

6. Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99:922–9.

7. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.

8. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985–96.

9. Hill A, Sapsford RJ, Scally A, Kelly R, Richards SJ, Khurisgara G, et al. Under-recogized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol. 2012;158:409–14.

10. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood. 1982;60:20–3.

11. Bourantas K. High-dose recombinant human erythropoietin and low-dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria. Acta Haematol. 1994;91:62–5.

12. Issaragrisil S, Piankijagum A, Tang-narisorana Y. Corticosteroids therapy in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 1987;25:77–83.

13. Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, et al. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. J Korean Med Sci. 2016;31:214–21.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit